Upper body mobility: A crucial focus in FSHD treatment by Anna Gilmore, FSHD Society On August 23, 2024, the FSHD Society brought a fresh perspective to the Food and Drug… Read More »
FDA Patient Listening Session
Avidity begins Cohort C enrollment in FORTITUDE trial
Avidity begins Cohort C enrollment in FORTITUDE trial Avidity Biosciences has begun enrollment of Cohort C of the Phase 1/2 FORTITUDE™ clinical trial. Below is Avidity’s letter to the FSHD… Read More »
Mighty micro RNAs
by Yi-Wen Chen, PhD, Children’s National Hospital, Washington DC Many Nobel Prize-winning discoveries have contributed to the advancement of research and treatments for facioscapulohumeral muscular dystrophy (FSHD), and the work… Read More »
Fulcrum halts losmapimod development
Fulcrum halts losmapimod development by June Kinoshita This morning, we received news Fulcrum has decided to halt its development of losmapimod (see press release below). Fulcrum’s decision was based on… Read More »
A note to our families from CEO Mark Stone
A note to our families This morning, Fulcrum released top-line results of its phase 3 trial for Losmapimod. The results showed no difference between placebo and active ingredient groups. Therefore,… Read More »